How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about enfortumab vedotin with pembrolizumab

Marketing authorisation indication

2.1

Enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) is indicated for 'the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum‑containing chemotherapy'.

Price

2.3

The price of enfortumab vedotin is £578 per 20-mg vial or £867 per 30-mg vial (excluding VAT; BNF online accessed March 2025). The price of pembrolizumab is £2,630 per 100 mg in a 4-ml vial (excluding VAT; BNF online accessed March 2025).

2.4

Astellas has a commercial arrangement for enfortumab vedotin. This makes enfortumab vedotin available to the NHS with a discount and it would have also applied to this indication if enfortumab vedotin with pembrolizumab had been recommended. The size of the discount is commercial in confidence.

2.5

MSD has a commercial arrangement for pembrolizumab. This makes pembrolizumab available to the NHS with a discount and it would have also applied to this indication if enfortumab vedotin with pembrolizumab had been recommended. The size of the discount is commercial in confidence.